Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients
Table 1
Baseline sociodemographic and clinical characteristics of study population by outcome (FIB-4).
Variable
Total ()
FIB-4 ≤ 3.25 ()
FIB-4 > 3.25 ()
Age (years)
55 (10.7)
54.5 (11.2)
57.8 (9.6)
<0.001
Male sex (%)
292 (66.4)
165 (65.7)
127 (67.2)
0.75
Caucasian ethnicity (%)
343 (78)
191 (76.1)
152 (80.4)
0.28
Indication for transplant (%)
Alcohol
96 (21.8)
59 (23.5)
37 (19.6)
<0.001
HCV
79 (18)
32 (12.7)
47 (24.9)
NASH
62 (14.1)
34 (13.5)
28 (14.8)
HBV
34 (7.7)
21 (8.4)
13 (6.9)
Others
169 (38.4)
105 (41.9)
64 (33.8)
Obesity (%)
125 (28.4)
70 (27.7)
55 (29)
0.78
Diabetes (%)
93 (21.1)
28 (11.2)
65 (34.4)
<0.001
MELD
22.3 (8.6)
22.1 (8.9)
22.8 (8.2)
0.5
MELD sodium
23.7 (8.2)
23.5 (8.5)
24.1 (7.6)
0.58
Hyponatremia (%)
132 (30)
65 (25.9)
67 (35.4)
0.03
Hypoalbuminemia (%)
150 (34.1)
58 (23)
92 (48.7)
<0.001
CMV pos recipient (%)
296 (67.3)
156 (62.2)
140 (74.1)
0.008
Cholesterol (mmol/L)
4.7 (1.5)
4.6 (1.5)
4.8 (1.4)
0.28
Donor age (years)
44 (17.7)
42.8 (16.7)
51 (15)
0.28
Cold ischemia time (hours)
8.4 (3)
8.3 (3.1)
87 (3)
0.25
Cyclosporine (%)
154 (35)
68 (27.1)
86 (45.5)
<0.001
Results given as mean (standard deviation) or (%). -test or chi-square test between “FIB-4 ≤ 3.25” and “FIB-4 ≤ 3.25.” BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; CMV, cytomegalovirus; HCC, hepatocellular carcinoma; MELD, model for end stage liver disease.
